Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd maintains a debt-to-equity ratio of 0.4, indicating a relatively conservative capital structure with a strong equity base. The company's liquidity position is characterized by a current ratio of 3.0, suggesting it has sufficient short-term assets to cover its liabilities. However, the company reported negative operating cash flow of -459.2 million INR and free cash flow of -823.4 million INR, signaling potential short-term liquidity constraints. The company's profitability metrics show a return on equity (ROE) of 7.45% and a return on assets (ROA) of 4.77%, which are below the industry median for pharmaceutical firms. This suggests that Senores Pharmaceuticals is underperforming in terms of capital efficiency and asset utilization compared to its peers. Senores Pharmaceuticals does not disclose segment-level revenue data, but its geographic exposure is primarily concentrated in India, with no material international operations reported. This concentration may expose the company to regulatory and macroeconomic risks specific to the Indian market. The company's revenue growth trajectory is not explicitly provided, but its operating income of 728.6 million INR and net income of 585.6 million INR suggest a stable, though not rapidly growing, business. Analysts have assigned a mean price target of 1,044.25 INR and a median price target of 1,101.00 INR, with a mean recommendation of 1.50, indicating a generally positive outlook. The risk assessment for Senores Pharmaceuticals highlights a medium liquidity risk due to negative operating and free cash flows, despite a strong current ratio. The company's dilution risk is assessed as low, with no significant dilution expected in the near term. However, the negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. Recent events include the publication of the latest financial data, which shows a capital expenditure of -1.575 billion INR, indicating a significant investment in long-term assets. No recent filings or transcripts have been disclosed that would suggest material changes in the company's strategic direction or financial health.